Insider Transactions in Q2 2021 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2021
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+12.34%
|
$27,000
$3.76 P/Share
|
|
Jun 24
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.71%
|
$406,250
$65.61 P/Share
|
|
Jun 24
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+0.71%
|
$12,500
$2.67 P/Share
|
|
Jun 21
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
489
+0.5%
|
$1,956
$4.31 P/Share
|
|
Jun 15
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
4,000
-29.65%
|
$256,000
$64.96 P/Share
|
|
Jun 15
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+22.87%
|
$60,000
$15.52 P/Share
|
|
Jun 15
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$160,000
$64.83 P/Share
|
|
Jun 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Jun 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.9%
|
$30,500
$61.84 P/Share
|
|
Jun 11
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$61,000
$61.55 P/Share
|
|
Jun 11
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.2 P/Share
|
|
Jun 10
2021
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
3,417
-11.36%
|
$205,020
$60.0 P/Share
|
|
Jun 08
2021
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,880
+34.98%
|
$398,800
$10.03 P/Share
|
|
Jun 01
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$56,000
$56.4 P/Share
|
|
Jun 01
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.76 P/Share
|
|
Jun 01
2021
|
A. Sinclair Dunlop Director |
BUY
Other acquisition or disposition
|
Indirect |
2,682
+0.88%
|
-
|
|
Jun 01
2021
|
A. Sinclair Dunlop Director |
BUY
Other acquisition or disposition
|
Direct |
13,108
+15.2%
|
-
|
|
Jun 01
2021
|
A. Sinclair Dunlop Director |
SELL
Other acquisition or disposition
|
Indirect |
31,855
-100.0%
|
-
|
|
May 28
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
489
+0.5%
|
$1,956
$4.31 P/Share
|
|
May 24
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.71%
|
$293,750
$47.4 P/Share
|
|
May 24
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+0.71%
|
$12,500
$2.67 P/Share
|
|
May 20
2021
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
5,773
-15.34%
|
$277,104
$48.1 P/Share
|
|
May 19
2021
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
7,612
-2.47%
|
$380,600
$50.0 P/Share
|
|
May 18
2021
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
149,488
-18.35%
|
$7,922,864
$53.17 P/Share
|
|
May 18
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
2,000
-17.41%
|
$110,000
$55.0 P/Share
|
|
May 18
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+14.83%
|
$30,000
$15.52 P/Share
|
|
May 14
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$112,500
$45.39 P/Share
|
|
May 14
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
May 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.89%
|
$22,500
$45.39 P/Share
|
|
May 03
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.07%
|
$30,000
$50.73 P/Share
|
|
May 03
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$50,000
$50.73 P/Share
|
|
May 03
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.76 P/Share
|
|
Apr 30
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$50,000
$50.0 P/Share
|
|
Apr 30
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.76 P/Share
|
|
Apr 28
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+0.51%
|
$9,000
$2.67 P/Share
|
|
Apr 23
2021
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.29%
|
$140,000
$14.0 P/Share
|
|
Apr 23
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.72%
|
$287,500
$46.13 P/Share
|
|
Apr 23
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+0.71%
|
$12,500
$2.67 P/Share
|
|
Apr 22
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
489
+0.5%
|
$1,956
$4.31 P/Share
|
|
Apr 21
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$112,500
$45.76 P/Share
|
|
Apr 21
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Apr 16
2021
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$700,000
$14.0 P/Share
|
|
Apr 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.88%
|
$21,000
$42.82 P/Share
|
|
Apr 01
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.05%
|
$25,800
$43.41 P/Share
|